N
IBIO icon

Natixis’s iBio IBIO Stock Holding History

Natixis’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-386
Closed -$33K – 1215
2022
Q3 		$33K Buy
+386
New +$53.1K ﹤0.01% 1015

Other funds holding IBIO

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Natixis's IBIO Position: Q4 2022 in Review

Natixis sold out of iBio (IBIO) in Q4 2022, closing a stake of 386 shares — an estimated $33K sold.

Natixis first reported a position in IBIO in Q3 2022 and held it in 1 quarter. The position peaked at $33K in Q3 2022. 36 funds tracked by Wall St. Rank hold IBIO as of Q4 2022.

  • Natixis reported no remaining iBio position as of Q4 2022 after selling out during the quarter.
  • Natixis sold 386 iBio shares in Q4 2022, an estimated $33K.
  • Natixis first reported a position in iBio in Q3 2022 and held it in 1 quarter.
  • Natixis's iBio position peaked at $33K in Q3 2022.
  • 36 funds tracked by Wall St. Rank held iBio as of Q4 2022.

Based on Natixis's 13F filing for Q4 2022, filed 13 Feb 2023.